Glycated albumin (GA)

Glycated albumin is a collective term for albumin molecules in plasma that have undergone non-enzymatic glycation, primarily at lysine residues, forming stable Amadori adducts such as fructoselysine[2][1][3]. This process is strongly dependent on circulating glucose concentrations and reflects mean glycemia over the preceding 2–3 weeks, corresponding to albumin’s half-life[3][5]. Glycated albumin acts as a key *biomarker* rather than a molecular drug target, having particular value in diabetes for monitoring short- and intermediate-term glycemic control, especially when HbA1c cannot be reliably measured[2][5]. It impacts albumin’s structure and function, potentially affecting ligand binding and antioxidant capacity, and may play roles in pathophysiology related to diabetes complications, endothelial dysfunction, and cardiovascular risk[1][5][7]. Glycated albumin is not a receptor, enzyme, transporter, or classical drug target, but a post-translationally modified protein—a state of albumin reflecting metabolic glycemic history[2][3].

Other names

Glycated human serum albuminGlycoalbuminGAFructosyl albumin